• EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Enabling Precision Cytokine

  2026-06-22

  Explore how EZ Cap™ Mouse IL-12 mRNA (m1Ψ) empowers next-generation cytokine engineering for immunotherapy research. This article reveals advanced extrahepatic mRNA delivery strategies and practical assay innovations distinct from prior guides.

• Latrunculin A: Reversible Inhibitor of Actin Assembly in Act

  2026-06-22

  Latrunculin A is transforming cell biology workflows by enabling precise, rapid, and reversible disruption of actin dynamics. From dissecting cytoskeletal responses in tumor models to probing mechanosensitive pathways in neural regeneration, APExBIO’s Latrunculin A empowers reproducible, high-impact experiments.

• Temafloxacin: Fluoroquinolone Broad-Spectrum Antibacterial A

  2026-06-21

  Temafloxacin distinguishes itself as a fluoroquinolone broad-spectrum antibacterial agent with exceptional activity profiles against both Gram-positive and Gram-negative pathogens. This article unpacks real-world workflows, data-driven assay enhancements, and troubleshooting strategies to maximize research reproducibility and translational insight.

• Temafloxacin: Optimizing Fluoroquinolone Antibacterial Workf

  2026-06-20

  Temafloxacin stands out as a fluoroquinolone broad-spectrum antibacterial agent with exceptional bioavailability and tissue penetration, enabling robust research on Gram-positive, Gram-negative, and atypical pathogens. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights to maximize assay reliability and translational impact.

• Reliable Workflows with GTP Solution (100 mM): Protocols & D

  2026-06-19

  This article provides scenario-driven guidance for using GTP Solution (100 mM) (SKU K1044) in cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed evidence and practical lab challenges, it details how this high-purity guanosine-5'-triphosphate supports reproducibility and data integrity in sensitive molecular workflows. Scientists can leverage these insights to optimize protocols and ensure reliable results.

• Chemically Modified TPO mRNA Boosts Platelet Production in M

  2026-06-19

  The referenced study demonstrates that in vitro-transcribed, chemically modified mRNA encoding thrombopoietin (TPO) can robustly stimulate platelet production in mice after lipid nanoparticle-mediated delivery. This work establishes mRNA-based TPO therapy as a promising, mechanistically distinct approach for treating thrombocytopenia, with implications for the design of next-generation mRNA therapeutics.

• Serotonin Inhibits HRP-Mediated Proximity Labeling: Mechanis

  2026-06-18

  This study reveals that serotonin selectively inhibits HRP-catalyzed proximity labeling using membrane-impermeant biotinylated tyramide probes, a previously unrecognized confounder in neuronal proteomics. The authors demonstrate that serotonin, but not dopamine, suppresses biotinylation, and introduce a chemical strategy to restore labeling efficacy, thus refining experimental design for spatial proteomics in neuroscience.

• Aztreonam: Advanced Mechanistic Insights and Research Protoc

  2026-06-18

  Explore the multifaceted scientific applications of Aztreonam, a monocyclic β-lactam antibiotic, with a focus on its molecular action, unique effects on hepatic enzymes, and protocol optimization for Gram-negative research. Distinct from existing resources, this article delivers actionable, evidence-grounded guidance for experimentalists.

• Palonosetron Hydrochloride: Precision 5-HT3 Receptor Antagon

  2026-06-17

  Palonosetron hydrochloride sets the benchmark for 5-HT3 receptor antagonist research, combining nanomolar potency, dual-site allosteric action, and unrivaled selectivity. Explore optimal applications in CINV/RINV modeling, renal transporter inhibition, and stepwise troubleshooting—empowering oncology and pharmacology labs with superior reproducibility.

• Levofloxacin in Research: Applied Workflows and Resistance I

  2026-06-17

  Levofloxacin, a synthetic fluoroquinolone antibiotic, empowers researchers to dissect bacterial DNA replication and explore bone and cartilage metabolism with precision. This guide delivers practical workflows, troubleshooting strategies, and integrates new resistance findings to help optimize both microbiological and cell-based assays.

• Vemurafenib (PLX4032): Systems Biology Insights for Melanoma

  2026-06-16

  Explore how Vemurafenib (PLX4032) advances melanoma cell proliferation inhibition and resistance analysis. This article uniquely integrates multi-omics findings and practical assay considerations for cancer biology research.

• Clarithromycin as a CYP3A Inhibitor: Advanced DDI Workflow G

  2026-06-16

  Clarithromycin, a potent CYP3A inhibitor, is an essential tool for mechanistic pharmacokinetic and drug-drug interaction (DDI) research, particularly in cardiovascular and metabolic contexts. This article delivers a practical, protocol-driven guide for optimizing Clarithromycin-based workflows, drawing on the latest evidence to ensure reproducible results and actionable insights.

• Quercetin as a PI3K Inhibitor: Experimental Workflows & Opti

  2026-06-15

  Quercetin is redefining PI3K inhibition in cancer and liver injury research, offering robust, reproducible modulation of cell death pathways. Explore applied protocols, advanced troubleshooting, and key translational insights that set APExBIO's Quercetin apart for modern biomedical assays.

• Levofloxacin in Research: Beyond Antibacterial Action to Bon

  2026-06-15

  Explore how Levofloxacin, a synthetic fluoroquinolone antibiotic, is redefining advanced research into bacterial DNA replication and bone/cartilage metabolism. This article uniquely integrates recent multidrug resistance insights with practical assay considerations for scientific investigators.

• ERADECs: Small-Molecule Hijacking of ERAD for TM Protein Deg

  2026-06-14

  Song et al. (2026) introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that leverages the endoplasmic reticulum-associated degradation (ERAD) pathway to selectively degrade transmembrane proteins. This breakthrough addresses long-standing barriers in targeted protein degradation and opens new directions for research in membrane protein modulation and disease intervention.

455 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page